SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Seres brings the microbiome back to life
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
Kevzara's Covid-19 setback shows need for hard evidence
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
